These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 30651063

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.
    Lehmann S, Ringbæk T, Løkke A, Grote L, Hedner J, Lindberg E.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():199-210. PubMed ID: 30666100
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A.
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
    Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, FLAME Investigators.
    N Engl J Med; 2016 Jun 09; 374(23):2222-34. PubMed ID: 27181606
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Coexisting Heart Failure and Chronic Obstructive Pulmonary Disease: Report of Two Cases Treated with Indacaterol/Glycopyrronium.
    Cosentino ER, Degli Esposti D, Miceli R, Bentivenga C, Landolfo M, Ricci Iamino I, Spinardi L, Magri G, Borghi C.
    Respiration; 2018 Jun 09; 95 Suppl 1():3-5. PubMed ID: 29705784
    [Abstract] [Full Text] [Related]

  • 33. Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.
    Kang J, Kim KT, Lee JH, Kim EK, Kim TH, Yoo KH, Lee JS, Kim WJ, Kim JH, Oh YM.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 09; 12():3557-3565. PubMed ID: 29263660
    [Abstract] [Full Text] [Related]

  • 34. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
    Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 09; 12():1325-1337. PubMed ID: 28496316
    [Abstract] [Full Text] [Related]

  • 35. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.
    Lung; 2017 Dec 09; 195(6):739-747. PubMed ID: 28993871
    [Abstract] [Full Text] [Related]

  • 36. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 Dec 09; 15():43-56. PubMed ID: 32021143
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
    Plate T, Friedrich FW, Beier J.
    Int J Chron Obstruct Pulmon Dis; 2020 Dec 09; 15():1335-1347. PubMed ID: 32606643
    [Abstract] [Full Text] [Related]

  • 38. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N, Kaneko T.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec 09; 10():813-22. PubMed ID: 25960646
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, Lim SY, Shim JJ, Lee YC, Kim YS, Oh YM, Kim S, Yoo CG.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 09; 12():1589-1596. PubMed ID: 28615931
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.